MaaT Pharma: Half-year Report and an Increase of the Resources Allocated to the Liquidity Contract With Kepler Cheuvreux

05 Jul 2024 18:00 CEST

Regulatory News:

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies^TM (MET) dedicated to enhancing survival for patients with cancer, today announces its half-year report on the liquidity contract with the firm Kepler Cheuvreux and an increase of €50,000 to the resources allocated to the contract, in accordance with the provisions of article 4 of AMF decision no. 2021-01 of June 22, 2021.

Under the liquidity contract entered into between Maat Pharma and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30^th, 2024:

• 26,929 shares
• € 17,089.40
• Number of executions on buy side on semester: 933
• Number of executions on sell side on semester: 1,014
• Traded volume on buy side on semester: 28,959 shares for € 237,891.32
• Traded volume on sell side on semester: 26,266 shares for € 220,168.07

As a reminder:

• the following resources appeared on the last half year statement on December 31, 2023 on the liquidity account:

• 24,236 shares
• € 34,107.60
• Number of executions on buy side on semester: 627
• Number of executions on sell side on semester: 368
• Traded volume on buy side on semester: 18,328 shares for € 122,340.49
• Traded volume on sell side on semester: 9,576 shares for € 64,693.03

• the following resources appeared on the liquidity account when the activity started:

• 0 shares
• € 200,000.00

Following the addition of these resources for the amount of €50,000, the position on July 4^th, 2024, is:

• 26,006 shares
• € 74,303.08

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22^nd, 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.

About MaaT Pharma

MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint^®, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).

View source version on businesswire.com: https://www.businesswire.com/news/home/20240705981889/en/

MaaT Pharma – Investor Relations
Guilhaume DEBROAS, Ph.D.
Head of Investor Relations
+33 6 16 48 92 50
invest@maat-pharma.com

MaaT Pharma – Media Relations
Pauline RICHAUD
Senior PR & Corporate Communications Manager
+33 6 14 06 45 92
media@maat-pharma.com

Trophic Communications
Jacob VERGHESE or
Desmond JAMES
+49 151 7441 6179
maat@trophic.eu